EMEA-002559-PIP01-19

Key facts

Active substance
Anti-neonatal Fc receptor human monoclonal antibody
Therapeutic area
Other
Decision number
P/0288/2019
PIP number
EMEA-002559-PIP01-19
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Prevention of haemolytic disease of the foetus and newborn
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Janssen-Cilag International NV

E-mail: contact@janssen-emea.com
Tel. +32 1460 2111

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating
Average
1 rating